Oleksii S. Rukhlenko

1 week ago | biorxiv.org | Luke Jones |Oleksii S. Rukhlenko |Tânia R Dias |Hiroaki Imoto

AbstractMutations activating RAS/RAF/MEK/ERK signaling are associated with poor outcome in acute myeloid leukemia (AML), but therapeutic targeting of this pathway is challenging. Here, we employ a structure-based, dynamic RAS pathway model to successfully predict RAF inhibitor (RAFi) combinations which synergistically suppress ERK signaling in RAS-mutant AML.